[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mouth-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mouth-neoplasms":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,79,117,146,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641279","tissue-adhesive-versus-sutures-in-oral-biopsy-closure-100641279",false,"NCT07654166","Tissue Adhesive Versus Sutures in Oral Biopsy Closure","Comparison of Tissue Adhesive and Surgical Sutures for Wound Closure After Oral Excisional Biopsies: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n-Patients clinically diagnosed with oral fibroma located on the\n\nlabial mucosa (lip) or buccal mucosa (cheek).\n\n* Lesion requires excisional biopsy.\n* Lesion size greater than 3 mm and less than 3 cm in\n\ngreatest diameter.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Patients taking anticoagulant medications (blood thinners).\n* Patients with infectious diseases such as hepatitis, HIV, etc.\n* Patients taking immunosuppressants.\n* Patients with uncontrolled diabetes mellitus.\n* Patients taking medications that affect bleeding and wound healing.","ALL","18 Years","80 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"NA","Excisional biopsies are commonly performed in the oral mucosa, and proper wound closure and hemostasis are critical for the success of the surgical procedure. Suturing remains the gold standard for closing surgical incisions; however, it has several drawbacks, including being time-consuming and requiring technical skill for proper placement. In addition, access to posterior areas of the oral cavity can be challenging. Suturing may also cause patient discomfort during needle penetration of tissues and can serve as a potential pathway for microbial contamination. Therefore, this randomized controlled clinical trial aims to evaluate one of the latest tissue adhesives from the cyanoacrylate group (PeriAcryl 90 HV) compared to conventional surgical sutures (Nylon 4-0) for wound closure following oral excisional biopsies. A total of 28 patients with oral fibroma will be randomly assigned to either the tissue adhesive group or the suture group (14 patients per group).",[27],"Mouth Neoplasms",[29,30,31,32,33],"PeriAcryl 90 HV","Oral fibroma","surgical sutures","excisional biopsy","tissue adhesive","RECRUITING","2026-06-16",{"date":37,"type":38},"2026-06-18","ACTUAL",{"date":40,"type":38},"2025-08-12",{"date":42,"type":21},"2027-12",{"name":44,"class":45},"Damascus University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":46},"100623823","effect-of-dezocine-versus-nalbuphine-combined-with-sufentanil-on-postoperative-analgesia-complications-and-free-flap-survival-in-patients-undergoing-oral-cancer-radical-surgery-a-randomized-controlled-clinical-trial-100623823","NCT07401641","Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial.","Inclusion Criteria:\n\n1. Diagnosed with oral malignant tumor.\n2. Scheduled for oral cancer radical surgery with free flap reconstruction at Sun Yat-sen Memorial Hospital.\n3. Age between 18 and 70 years.\n4. Sign informed consent.\n\nExclusion Criteria:\n\n1. Use of analgesic medications within two weeks prior to surgery.\n2. History of diabetes, arteriosclerosis, or peripheral vascular disease.\n3. Use of hormones, chemotherapy, or immunosuppressants.\n4. Severe cardiac, pulmonary, hematological, hepatic, or renal diseases.\n5. Known allergy to the study drugs.","70 Years",{"count":55,"type":21},60,[24],"Background: Oral cancer radical surgery often requires free flap reconstruction. Postoperative pain is severe, and traditional opioids like sufentanil have side effects and may adversely affect tumor biology. Dezocine and nalbuphine are opioid agonist-antagonists with potentially better safety profiles. Their comparative effects on analgesia, complications, and flap survival in oral cancer surgery are unknown.\n\nObjective: To compare the efficacy of dezocine versus nalbuphine, both combined with sufentanil, for postoperative analgesia, and to evaluate their impact on postoperative complications and free flap survival\u002Ffunction in patients undergoing oral cancer radical surgery with flap reconstruction.\n\nMethods: This is a prospective, randomized, double-blind, controlled trial. Sixty eligible patients (aged 18-70, ASA I-III) will be randomly assigned (1:1) to receive postoperative patient-controlled intravenous analgesia (PCIA) with either Sufentanil + Dezocine or Sufentanil + Nalbuphine. The primary outcome is pain intensity assessed by the Visual Analogue Scale (VAS) at 2, 24, and 48 hours postoperatively. Secondary outcomes include flap survival status, sensory function recovery, incidence of adverse events (e.g., nausea, vomiting), and hospitalization duration.\n\nPotential Impact: This study may identify a superior postoperative analgesic regimen that provides effective pain relief while potentially improving flap outcomes and minimizing side effects for oral cancer patients.",[59,60,61,27],"Oral Cancer","Postoperative Pain Management","Free Tissue Flaps",[63,64,65,66,67,68,69],"Dezocine","Nalbuphine","Oral Cancer Surgery","Free Flap Reconstruction","Postoperative Analgesia","Randomized Controlled Trial","Flap Survival","2026-02-03",{"date":72,"type":38},"2026-02-10",{"date":74,"type":38},"2025-06-01",{"date":76,"type":21},"2026-06-01",{"name":78,"class":45},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":98,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":116},"100498763","sentinel-node-biopsy-versus-limited-elective-neck-dissection-in-early-cancers-of-oral-cavity-node-negative-100498763","NCT05774483","Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative","Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative (SECOND N0): Non-inferiority Phase III Trial","SECOND N0","Inclusion Criteria:\n\n1. Age \\>18 years of age\n2. Biopsy-proven invasive squamous cell carcinoma involving the site tongue and buccal mucosa\n3. T1 and T2 lesions as per AJCC TNM 8 edition\n4. Clinicoradiologically node negative\n5. Amenable to per oral excision\n6. Treatment naïve\n7. No other site of malignancy\n\nExclusion Criteria:\n\n1. Previous surgery in the head and neck region,\n2. Upper alveolar or palatal lesions\n3. Large heterogeneous leukoplakia or other premalignant lesions\n4. Previous malignancy in the head and neck region\n5. Patients requiring the free flap reconstruction",{"count":88,"type":21},508,[24],"The goal of this clinical trial is to compare the survival outcomes, morbidity and cost-effectiveness of sentinel node biopsy versus limited elective neck dissection in node-negative early oral cancers.\n\nThe main questions it aims to answer are:\n\n* Survival outcomes\n* Morbidity outcomes\n* Cost-effectiveness\n\nParticipants will either undergo sentinel node biopsy followed by completion neck dissection if sentinel node is reported to be metastatic (SNB) or limited elective neck dissection where level IIb will be cleared only if level IIa is metastatic (limited END). The study will compare the outcomes in the two cohorts.",[27,92,93,94,95,96,97],"Oral Cancers","Oral Squamous Cell Carcinoma (OSCC)","Oral Squamous Cell Carcinomas","Sentinel Lymph Node Biopsy","Sentinel Lymph Node Biopsy (SLNB)","Sentinel Lymph Node",[99,100,101,102,103,104,105],"mouth neoplasms","neck dissection","sentinel lymph node biopsy","survival","morbidity","oral cancers","oral squamous cell carcinoma","2025-07-14",{"date":108,"type":38},"2025-07-17",{"date":110,"type":38},"2025-04-16",{"date":112,"type":21},"2034-04",{"name":114,"class":115},"Tata Memorial Hospital","OTHER_GOV",3,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":46},"100581294","phase-2-benmelstobart-anlotinib-chemo-for-neoadjuvant-oral-cancer-100581294","NCT06848439","Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer","A Phase II Study of Benmelstobart Combined With Anlotinib and Chemotherapy as Neoadjuvant Therapy Followed by Surgery and Postoperative Radiotherapy in Patients With Locally Advanced Oral Cancer","Inclusion Criteria:\n\n* Potential subjects must meet all of the following criteria to be eligible for inclusion in this study:\n* Age 18-75 years;\n* ECOG PS score of 0-1;\n* Pathologically confirmed untreated oral squamous cell carcinoma patients, classified as stage III-IVb according to the AJCC (8th edition) staging system;\n* Women of childbearing potential must have taken reliable contraceptive measures or have a negative pregnancy test (serum or urine) within 7 days prior to enrollment, and be willing to use appropriate contraceptive methods during the trial and for 8 weeks after the last dose of the study drug, or be surgically sterilized. For men, they must agree to use appropriate contraceptive methods during the trial and for 8 weeks after the last dose of the study drug, or be surgically sterilized;\n\nSigned informed consent form by the participant, with good compliance.\n\nExclusion Criteria:\n\nPotential subjects must be excluded from the study if they meet any of the following criteria:\n\n* Prior treatment with PD-1\u002FPD-L1\u002FCTLA-4 antibodies.\n* Tumor invasion of major blood vessels.\n* Requirement for systemic corticosteroid therapy (\\>10 mg prednisone equivalent per day) or other immunosuppressive treatment within 14 days before administration or during treatment. Inhaled or topical steroids and adrenal corticosteroid replacement therapy at ≤10 mg\u002Fday prednisone equivalent are allowed in the absence of active autoimmune disease.\n* History of any active immune-related or autoimmune disease, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Active or uncontrolled severe infection (≥ Grade 2 NCI CTCAE v5.0 infection) within 4 weeks prior to enrollment.\n* Coagulation disorders (INR \\>1.5, prothrombin time (PT) \\> ULN + 4 sec, or APTT \\>1.5 × ULN), a tendency for bleeding, or undergoing thrombolytic or anticoagulant therapy. Note: The use of low-dose heparin (adult daily dose of 6,000-12,000 U) or low-dose aspirin (daily dose ≤100 mg) for prophylactic purposes is allowed if INR ≤1.5.\n* Imaging evidence of tumor invasion of major blood vessels or tumors highly likely to invade major blood vessels and cause fatal hemorrhage during the study, as assessed by the investigator.\n* Any signs or history of a bleeding tendency, regardless of severity. Patients with bleeding or hemorrhagic events (≥CTCAE Grade 2) within 4 weeks prior to randomization, or those with unhealed wounds, ulcers, or fractures.\n* Major organ dysfunction:\n\nHematological abnormalities (without correction via blood transfusion, blood products, G-CSF, or other hematopoietic stimulants within 14 days):\n\n1. Hemoglobin (HB) \\\u003C90 g\u002FL.\n2. Absolute neutrophil count (ANC) \\\u003C1.5 × 10⁹\u002FL.\n3. Platelets (PLT) \\\u003C100 × 10⁹\u002FL.\n\nBiochemical abnormalities:\n\n1. Total bilirubin (TBIL) \\>1.5 × ULN.\n2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\>2.5 × ULN.\n3. Serum creatinine (Cr) \\>1.5 × ULN or creatinine clearance rate (CCr) \\\u003C60 mL\u002Fmin. Doppler ultrasound abnormalities: Left ventricular ejection fraction (LVEF) \\\u003C60%.\n\nThyroid function abnormalities: TSH \\> ULN with abnormal T3 and T4 levels. Renal dysfunction: Urine protein ≥++ on urinalysis or confirmed 24-hour urine protein level ≥1.0 g.\n\n* History of myocardial ischemia (≥Grade I), myocardial infarction, arrhythmia (QTc ≥480 ms), or ≥Grade 2 congestive heart failure (NYHA classification) within 6 months before enrollment.\n* Diagnosis of another malignancy within 3 years prior to enrollment.\n* Any severe and\u002For uncontrolled disease, including:\n\n  1. Poorly controlled hypertension (systolic BP ≥150 mmHg or diastolic BP ≥100 mmHg), history of myocardial ischemia (≥Grade I), myocardial infarction, arrhythmia (QT interval ≥430 ms), or heart failure (NYHA Grade I).\n  2. Active or uncontrolled severe infection.\n  3. Liver cirrhosis, decompensated liver disease, or active hepatitis (HBV or HCV).\n  4. Poorly controlled diabetes (fasting blood glucose (FBG) \\>10 mmol\u002FL).\n  5. Urine protein ≥2+ and confirmed 24-hour urine protein \\>1.0 g.\n* Presence of long-term unhealed wounds or fractures.\n* Lung hemorrhage (\\>Grade 1 NCI CTC AE v4.0) within 4 weeks before enrollment or hemorrhage in other areas (\\>Grade 2 NCI CTC AE v4.0) within 4 weeks before enrollment. Patients with a tendency to bleed (e.g., active gastrointestinal ulcers) or those receiving thrombolytic or anticoagulant therapy (e.g., warfarin, heparin, or similar agents).\n* History of gastrointestinal perforation and\u002For fistula within 6 months before treatment initiation; or history of arterial\u002Fvenous thrombotic events, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism.\n* Imaging evidence of tumor invasion of major blood vessels or tumors highly likely to invade major blood vessels and cause fatal hemorrhage, as assessed by the investigator.\n* Clinically significant ascites, including any detectable ascites on physical examination or ascites requiring treatment. Patients with only mild asymptomatic ascites detected by imaging may be enrolled.\n* Uncontrolled metabolic disorders or other non-malignant systemic diseases or conditions secondary to cancer that may pose a high medical risk and\u002For create uncertainty in survival assessment.\n* Participation in other anti-tumor clinical trials within 4 weeks prior to enrollment.\n* History of substance abuse that cannot be discontinued or the presence of psychiatric disorders.\n* Any other conditions determined by the investigator that may pose serious risks to patient safety, confound study results, or affect the patient's ability to complete the study.","75 Years",{"count":126,"type":21},26,[128],"PHASE2","Exploring the Safety and Efficacy of Benmelstobart Combined with Anlotinib and Chemotherapy as Neoadjuvant Therapy Followed by Surgery and Postoperative Radiotherapy in Patients with Locally Advanced Oral Cancer\n\nThis is a single-center, Phase II study targeting patients with stage III-IVb locally advanced oral squamous cell carcinoma who meet the inclusion and exclusion criteria. The neoadjuvant therapy consists of Benmelstobart combined with Anlotinib and chemotherapy for 3 cycles (21 days per cycle). Surgery is performed within 2 weeks after completing neoadjuvant therapy. Postoperative adjuvant treatment is selected based on pathological grading:\n\nGroup A (Pathological Complete Response, pCR): Postoperative radiotherapy (RT) alone: 40Gy\u002F5 weeks.\n\nGroup B (Major Pathological Response, MPR): Postoperative radiotherapy (RT) alone: 50Gy\u002F5 weeks.\n\nGroup C (Partial Pathological Response\u002FNo Pathological Response):\n\nLow-to-intermediate risk patients (no extracapsular nodal extension and negative margins): RT: 60Gy\u002F6 weeks.\n\nHigh-risk patients (extracapsular nodal extension and\u002For positive margins): Concurrent chemoradiotherapy (CCRT): 60-66Gy\u002F6-6.6 weeks + Cisplatin: 60mg\u002Fm² every 3 weeks, 2-3 cycles.\n\nAdditionally, all patients will receive adjuvant Benmelstobart 3-4 weeks after surgery, followed by Benmelstobart maintenance therapy (total treatment duration of 1 year).",[27,131,132,133],"Neoadjuvant Therapy","Immunotherapy","Molecular Targeted Therapy",[27,135,132,133],"Neoadjuvant therapy","NOT_YET_RECRUITING","2025-05-27",{"date":139,"type":38},"2025-05-31",{"date":141,"type":21},"2025-06-15",{"date":143,"type":21},"2028-12-31",{"name":145,"class":45},"Jiangsu Cancer Institute & Hospital",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":124,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":46},"100231401","phase-2-cyclin-d1-based-tpf-induction-chemotherapy-for-oral-squamous-cell-carcinoma-patients-at-clinical-n2-stage-100231401","NCT02290145","Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage","Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial","Inclusion Criteria:\n\n* Age: 18 to 75 years old.\n* Sex: both males and females.\n* Karnofsky performance status (KPS) \\>60.\n* Histological biopsy confirming squamous cell carcinoma of the oral cavity (tongue, gingiva, buccal mucosa, floor of mouth, palate, and retromolar region).\n* Cyclin D1 high expression\n* Clinical stage III\u002FIVA (T1-2, N2, M0 or T3-4, N2, M0, UICC\\[International Union Against Cancer\\] 2002) with resectable lesions.\n* Adequate hematologic function: white blood cell \\>3,000\u002Fmm3, hemoglobin\\>8g\u002FL, platelet count\\>80,000\u002Fmm3.\n* Hepatic function: ALAT(alanine aminotransferase)\u002FASAT(aspartate transaminase) \\\u003C2.5 times the upper limit of normal (ULN), bilirubin \\\u003C1.5 times ULN.\n* Renal function: serum creatinine \\\u003C1.5 times ULN.\n* Written informed consent\n\nExclusion Criteria:\n\n* Evidence of distant metastatic disease and other cancers.\n* Surgical procedure of the primary tumors or lymph nodes (except diagnostic biopsy).\n* Previous radiotherapy or chemotherapy.\n* Other previous malignancies within 5 years.\n* Can not tolerate the treatment protocol with systematic diseases such as history of severe pulmonary or cardiac diseases.\n* Legal incapacity or limited legal capacity.\n* Creatinine clearance \\\u003C30ml\u002Fmin.\n* Pregnancy (confirmed by serum or urine β-HCG) or lactation period.",{"count":154,"type":21},48,[128],"The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC",[27,158],"Carcinoma, Squamous Cell",[160],"docetaxel, cisplatin, 5-FU, cyclinD1","2023-11-21",{"date":163,"type":38},"2023-11-22",{"date":165,"type":4},"2016-12",{"date":167,"type":21},"2026-12",{"name":169,"class":45},"Shanghai Jiao Tong University School of Medicine",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":178,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":46},"100462075","oral-cancer-screening-for-early-detection-of-premalignant-disorders-pmod-100462075","NCT05296941","Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD)","Screening for Oral Cancer for Early Detection of Premalignant Disorders","PMOD","Inclusion Criteria:\n\n• Persons 18 years of age or older who have the clinical diagnosis of leukoplakia, erythroplakia or proliferative verrukös leukoplakia\n\nExclusion Criteria:\n\n* People who cannot read and understand information in Swedish.\n* Ongoing chemotherapy and\u002For radiotherapy.",true,{"count":180,"type":21},200,[24],"Cancer is a complex disease; its different causes and types have a strong impact on patient treatment and prognosis. To improve understanding of the disease, its causes and progression, the investigators will develop a simple, cost-effective system for continuous control of mucosal lesions with non-invasive brush biopsy that can be managed in primary dental care, as an alternative to tissue biopsy in order to reduce the number of oral cavity cancers.",[27],[185,186,187,188,189],"oral cancer","potentially malignant disorders","leukoplakia","erythroplakia","oral lichen planus","2023-09-06",{"date":192,"type":38},"2023-09-08",{"date":194,"type":38},"2023-08-01",{"date":196,"type":21},"2029-12-31",{"name":198,"class":45},"Dalarna County Council, Sweden"]